Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEAâ„¢ (aflibercept) Injection
ST. LOUIS, Jan. 4, 2012 /PRNewswire/ -- Express Scripts now provides services for EYLEA, a product of Regeneron, through its HealthBridge Pharma & Biotech services. CuraScript, a wholly owned subsidiary of Express Scripts and part of the HealthBridge suite of services, will be among a limited number of specialty pharmacies and specialty distributors for EYLEA.
EYLEA (aflibercept) Injection was approved by the Food and Drug Administration on Nov. 18 and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Macular degeneration is diagnosed as either dry (non-vascular) or wet (vascular) and is a leading cause of blindness in older adults. The wet form usually leads to more serious vision loss.
"With a growing aging population, more and more people are affected by macular degeneration," explains Rob Osborne, Express Scripts senior director, business development, Pharma & Biotech. "HealthBridge Pharma & Biotech is proud to provide services that will help patients get the medication they need to treat this debilitating disease."
About HealthBridge Pharma & Biotech
HealthBridge Pharma & Biotech provides a suite of services offering pharmaceutical and biotech companies a single solution approach to patient care. These services include: CuraScript SP Specialty Pharmacy, CuraScript SD Specialty Distribution, Freedom Fertility Pharmacy, risk evaluation and mitigation strategies (REMS), reimbursement, patient assistance programs, data and sales reporting, enhanced account services, and customized adherence programs. More information can be found at http://www.TheHealthBridgeSolution.com/.
As a service of HealthBridge Pharma & Biotech, CuraScript Specialty Pharmacy is a wholly owned subsidiary of Express Scripts. CuraScript manages the largest number of exclusive Pharma & Biotech programs in the industry and has